IL161553A0 - Methods and compositions for inducing tumor-specific cytotoxicity - Google Patents

Methods and compositions for inducing tumor-specific cytotoxicity

Info

Publication number
IL161553A0
IL161553A0 IL16155302A IL16155302A IL161553A0 IL 161553 A0 IL161553 A0 IL 161553A0 IL 16155302 A IL16155302 A IL 16155302A IL 16155302 A IL16155302 A IL 16155302A IL 161553 A0 IL161553 A0 IL 161553A0
Authority
IL
Israel
Prior art keywords
compositions
methods
specific cytotoxicity
inducing tumor
tumor
Prior art date
Application number
IL16155302A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of IL161553A0 publication Critical patent/IL161553A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16155302A 2001-10-22 2002-10-22 Methods and compositions for inducing tumor-specific cytotoxicity IL161553A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/012,131 US7041654B2 (en) 1997-10-03 2001-10-22 Methods and compositions for inducing tumor-specific cytotoxicity
PCT/IL2002/000843 WO2003035883A2 (fr) 2001-10-22 2002-10-22 Procedes et compositions d'induction de cytotoxicite a specificite tumorale

Publications (1)

Publication Number Publication Date
IL161553A0 true IL161553A0 (en) 2004-09-27

Family

ID=21753530

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16155302A IL161553A0 (en) 2001-10-22 2002-10-22 Methods and compositions for inducing tumor-specific cytotoxicity

Country Status (8)

Country Link
US (1) US7041654B2 (fr)
EP (1) EP1438412A2 (fr)
JP (1) JP2005506386A (fr)
CN (1) CN1608135A (fr)
CA (1) CA2464394A1 (fr)
IL (1) IL161553A0 (fr)
MX (1) MXPA04003732A (fr)
WO (1) WO2003035883A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081053A1 (en) * 2004-09-30 2008-04-03 Bedrosian Camille L Treatment Method
EP1863906A4 (fr) * 2005-03-07 2009-06-03 Robarts Res Inst Combinaison du virus du myxome et de la rapamycine utilisée dans un traitement thérapeutique
JP5383186B2 (ja) * 2005-07-07 2014-01-08 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド Ｈ１９をダウンレギュレートする核酸薬剤、及びそれを使用する方法
CA2675964C (fr) * 2007-01-16 2015-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents nucleotidiques de silencage de h19 destines au traitement de l'arthrite rhumatoide
US20100196403A1 (en) * 2007-01-29 2010-08-05 Jacob Hochman Antibody conjugates for circumventing multi-drug resistance
US9173964B2 (en) * 2007-10-25 2015-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Diphtheria toxin first open reading frame operably linked to an H19 promoter and a diphtheria toxin second open reading frame operably linked to an IGF-II promoter as nucleic acid construct
US8188252B2 (en) * 2008-11-17 2012-05-29 University Of Rochester Rad51 derived cancer cell specific promoters for targeted anti-cancer therapy
WO2010084488A1 (fr) 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Thérapie anticancéreuse ciblée entraînée par le promoteur de mir-21
WO2011136400A1 (fr) * 2010-04-26 2011-11-03 Green Cross Corporation Promoteur spécifique d'une tumeur et vecteur viral oncolytique le comprenant
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US20170363612A1 (en) * 2014-12-03 2017-12-21 Wayne State University Compositions and methods relating to proliferative disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699191B1 (fr) 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
IL108879A (en) 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (fr) 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
FR2725213B1 (fr) 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6087164A (en) 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
WO2001023004A1 (fr) 1999-09-30 2001-04-05 The Trustees Of The University Of Pennsylvania Adenovirus selectifs de synthese utilises en therapie anticancereuse

Also Published As

Publication number Publication date
JP2005506386A (ja) 2005-03-03
CN1608135A (zh) 2005-04-20
US7041654B2 (en) 2006-05-09
US20040082529A1 (en) 2004-04-29
CA2464394A1 (fr) 2003-05-01
WO2003035883A3 (fr) 2003-11-27
WO2003035883A2 (fr) 2003-05-01
MXPA04003732A (es) 2004-07-23
EP1438412A2 (fr) 2004-07-21

Similar Documents

Publication Publication Date Title
AU2002357119A8 (en) Mitocidal compositions and methods
IL227966A0 (en) Vaccination kit
GB0103170D0 (en) Vaccine composition
GB0103171D0 (en) Vaccine composition
EP1420829A4 (fr) Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
HK1065944A1 (en) Medicinal compositions
HUP0003745A3 (en) Methods and compositions for inducing tumor-specific cytotoxicity
EP1476067A4 (fr) Compositions et procedes contre le cancer
GB0108470D0 (en) Pharmaceutical compositions and their use
AU8852301A (en) Compositions and methods for inducing vasorelaxation
EP1450610A4 (fr) Compositions probiotiques
EP1509539A4 (fr) Compositions et procedes concernant le cancer
AU2002357748A8 (en) Osteopontin-related compositions and methods
IL161553A0 (en) Methods and compositions for inducing tumor-specific cytotoxicity
EP1469769A4 (fr) Nouvelles compositions et methodes contre le cancer
ZA200401211B (en) Antigenic compositions
EP1469870A4 (fr) Nouvelles compositions et methodes pour le traitement du cancer
AU2002366809A8 (en) Syn3 compositions and methods
IL153176A (en) Phenylpiperazines and pharmaceutical compositions comprising them
AU2002365136A8 (en) Compositions and methods for controlled release
AU2002359869A8 (en) Pak5-related compositions and methods
AU2002308648A1 (en) Compositions and methods for reducing cytotoxicity and inhibiting angiogenesis
GB0115893D0 (en) Formulations
EG23003A (en) Synergistic formulations
GB0124023D0 (en) Novel compositions and use